Pharmacology of BMN 250 administered via intracerebroventricular infusion once every 2 weeks for twenty-six weeks or longer in a canine model of mucopolysaccharidosis type IIIB
Author:
N. Matthew Ellinwood,Bethann Valentine,Andrew S. Hess,Jackie K. Jens,Elizabeth M. Snella,Wendy A. Ware,Shannon J. Hostetter,Gil Ben-Shlomo,Nicholas Jeffery,Sina Safayi,Jodi D. Smith,Suzanne T. Millman,Rebecca L. Parsons,Mark T. Butt et al.
Publication:
Molecular Genetics and Metabolism